TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06415708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab Combined With Bendamustine
Description: The treatment is divided into two phases: induction therapy and maintenance therapy Induction therapy: 6 cycles of obinutuzumab (1000 mg, IV) on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6 (28 days/cycle). Bendamustine (90 mg/m2, IV) on Days 1 and 2 of Cycles 1-6.~Maintenance therapy: Patients who achieved at least a partial response after 6 months of induction therapy were eligible to enter the maintenance phase, during which obinutuzumab (1000 mg, IV) was administered every 2 months for 2 years.
Study: NCT05338164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical cerclage
Description: McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
Study: NCT04548713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4% EDTA
Description: Sterile Catheter Lock Solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline Lock Solution
Study: NCT06295965

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT05832684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZVS101e
Description: ZVS101e contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human wild type CYP4V2 gene.
Study: NCT05725278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tiko Platform Behavioural cum mHealth Intervention
Description: Tiko platform is a mix of social franchising and social marketing concepts to promote health behaviours through rewards to health promoters (pro agents), healthcare providers (doctors and pharmacies), Beneficiaries (women needing FP and/or ANC services), and shop keepers and life-style service providers where beneficiaries, providers and promoters could use their rewards points. The health promoters could purchase from wholesale retailers products such as sanitary napkins, condoms and then resale these at profit. Beneficiaries were given discounts and their rewards points can be used as cash to avail certain lifestyle services at participating locations, and so did the health care providers. Pro agents also got incentives for recruiting the beneficiaries and after beneficiaries reached certain service access/use milestones. All this was integrated on a mHealth platform using smart phones and smart cards (for those without access to Tiko card).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care / Business as Usual
Description: Non-Users of Tiko did not use Tiko platform but they could access any health care provider or pharmacy to avail same services related to Family planning, antenatal care, postnatal care
Study: NCT05798858

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NIPT
Description: universal nipt in group a, NIPT for intermediate risk in Group B

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NIPT
Description: universal nipt in group a, NIPT for intermediate risk in Group B
Study: NCT05338554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered pcTBS protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (parallel to the hemispheric midline).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Magnetic stimulation was performed using a figure-eight coil connected to a Magstim Rapid2 system, All patients seat in a comfortable reclining chair and delivered 10HZ protocol using repetitive transcranial magnetic stimulation . The stimulation intensity was set to 80% of the resting motor threshold, which is measured as the minimal intensity of stimulation evoking an electromyographic response ≥50µV on the first dorsal interosseus muscle of the hand contralateral to the stimulated hemisphere in at least 5 out of 10 trials. For this measurement, a figure-of-eight coil is positioned over the hand motor hotspot and oriented perpendicular to the central sulcus (45° away from the hemispheric midline).
Study: NCT06025175

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level Lazer therapy
Description: 30 patients will receive low level lazer therapy 3 times a week for 12 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine exercises
Description: 30 patients will receive only routine exercises 3 times a week for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine exercises
Description: 30 patients will receive only routine exercises 3 times a week for 12 weeks.
Study: NCT05484271

Intervention type: PROCEDURE
Intervention: Rotator cuff repair
Description: The patients received the arthroscopic rotator cuff repair.

Intervention type: PROCEDURE
Intervention: Rotator cuff repair
Description: The patients received the arthroscopic rotator cuff repair.

Intervention type: PROCEDURE
Intervention: Rotator cuff repair
Description: The patients received the arthroscopic rotator cuff repair.
Study: NCT04926961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial magnetic stimulation (TMS)
Description: Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial magnetic stimulation (TMS)
Description: Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real transcranial magnetic stimulation (TMS)
Description: Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real transcranial magnetic stimulation (TMS)
Description: Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.
Study: NCT06527729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil-loaded liposomes
Description: Topical 1% sildenafil-loaded liposomes was applied twice daily for a period of 8 weeks over patchy alopecia areata of the scalp.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minoxidil gel
Description: Topical 5% minoxidil gel was applied twice daily for a period of 8 weeks.
Study: NCT05571085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Exercises
Description: Core stabilization exercises will be performed based on the program recommended by Jeffrey. Each session will take 40-50 minutes. The program consists of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period.

Intervention type: OTHER
Group type: OTHER
Intervention: PNF Exercise Program
Description: PNF exercises will consist of a 5-minute warm-up, 40-minute main exercise and a 5-minute cool-down period, with each session lasting 40-50 minutes.
Study: NCT06526845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Conference based rehabilitation
Description: All exercises in the brochure will be performed by patients via telerehabilitation. The exercises included in the exercise package are as follows:~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based rehabilitation
Description: Patient education will be provided by showing all exercises in practice. Brochures will then be given to patients so they can apply them at home. The exercises in the brochure are as follows;~* Post-isometric relaxation exercise and relaxation exercise with diaphragmatic breathing~* Neck Exercises: 5 neck exercises including cervical isometric flexion, extension, right and left lateral flexion and chin tuck exercises.~* Soft tissue-friction massage: It will be applied to the area where myofascial pain develops due to TMJD.~* Mandibular mobility exercises: opening and closing the mouth slowly and rhythmically, lateral movements, protrusion movement, hold-relax technique, jaw isometric exercises~* Stretching exercises: Stretching exercises for chewing muscles (masseter muscle stretching, temporalis muscle stretching, pterygoid muscle stretching).
Study: NCT06525441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based Diet
Description: Participants assigned to the plant-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from plant protein, and 25% from fat. The main dietary sources of plant protein will be soybeans, flat beans, nuts, grains, and algae.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Animal-based Diet
Description: Participants assigned to the animal-based diet group will be provided three meals daily for 3 weeks. Of the energy of each meal, 60% is from carbohydrates, 15% from animal protein, and 25% from fat. The main dietary sources of animal protein will be chicken, beef, pork, fish, eggs, and dairy products.
Study: NCT05136456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR1459 Low Dose
Description: SHR1459 oral tablets taken once daily (QD) for 24weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR1459 High Dose
Description: SHR1459 oral tablets taken once daily (QD) for 24 weeks
Study: NCT04579952

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: The current stimulation will be applied using 35 squares cm wide sponge electrodes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: The current stimulation will be applied using 35 squares cm wide sponge electrodes
Study: NCT05136456

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets taken once daily (QD) for 24 weeks
Study: NCT05354531

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior subcutaneous internal fixator ( INFIX)
Description: INFIX was invented based upon the same biomechanical principle as the traditional external fixator, but it is placed subcutaneously. It proved to be stiffer than the traditional external fixator, and at the same time eliminates the open pin tracts, which increased the infection rate and nursing care
Study: NCT05744661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Method
Description: Use of Rotary Master Apical file for the removal of Calcium Hydroxide Medicament from Root Canal System

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemomechanical Method
Description: Sonic Activation of Endodontic irrigants for the removal of Calcium Hydroxide from Root Canal System
Study: NCT06412237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RELab tenoexo
Description: The RELab tenoexo is a fully wearable and portable RHO developed at the Rehabilitation Engineering Laboratory (RELab) at ETH Zurich.
Study: NCT06468683

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: After preconditioning with chemotherapy, F01 will be evaluated.
Description: Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 25-30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 250-300 mg/ m\^2 (D-5\~D-3)
Study: NCT06418087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]
Description: Intravenous infusion of durvalumab 1500 mg on day 1 (induction phase) with carboplatin (AUC 5 on day 1), etoposide (100 mg/sqm on days 1-3) every 3 weeks, and durvalumab (1500 mg on day 1) administered every three weeks for up to 4 cycles (induction phase) or until progression of disease, unacceptable toxicity, patient refusal or loss of clinical benefit (for durvalumab).~Treatment with intravenous durvalumab (1500 mg on day 1) every 4 weeks ± 3 days (maintenance phase) will continue until completion of 24 courses (for a total of 28 courses, including the 4 courses of induction phase) or 2 years of treatment whichever occurs first, disease progression, unacceptable toxicity, patient refusal or loss of clinical benefit.
Study: NCT06344702

Intervention type: DEVICE
Intervention: CPAP
Description: 70% of nights use CPAP for more than 4 hours
Study: NCT05836597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual reality
Description: Virtual reality
Study: NCT05509829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: Negative pressure wound therapy using PICO14.
Study: NCT05700357

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPVB with 20 ml
Description: The thoracic paravertebral block will be applied to the patients with 20 ml of 0.25% bupivacaine under real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPVB with 25 ml
Description: The thoracic paravertebral block will be applied to the patients with 25 ml of 0.25% bupivacaine under real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPVB with 30 ml
Description: The thoracic paravertebral block will be applied to the patients with 30 ml of 0.25% bupivacaine under real-time ultrasound guidance.
Study: NCT04078139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The MP/RP group
Description: Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The RP group
Description: Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
Study: NCT04102228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1Hz inhibitory rTMS
Description: 20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1Hz sham rTMS
Description: 20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Modality Aphasia Therapy (M-MAT)
Description: Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Multi-Modality Aphasia Therapy (M-MAT)
Description: Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
Study: NCT04952532

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)
Description: The proposed study aims to collect pilot data to test the feasibility and acceptability of adjunctive neuroplasticity-based cognitive remediation on key treatment targets. The intervention will be delivered via telehealth to a sample of 36 Veterans with MDD and a history of a suicide attempt. The intervention will be delivered in 20 90-min sessions (2x/week for 10 weeks). Pre-, post, and follow-up assessments will be conducted to assess changes in neurocognitive, clinical, social, and real-world functioning.
Study: NCT06306027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based education
Description: The patient discharged after knee arthroplasty surgery will attend a follow-up appointment 15 days later, and during this visit, they will be granted permission to resume work. The patient will receive detailed information about accessing, entering, and using the web-based training. Scales with pre-test data will be completed by the patient. They will be encouraged to log in at least twice a week, and the patient will be monitored for a total of 1 month (4 weeks). After one month, the patient will be asked to fill out the scales again.
Study: NCT06257576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoreceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockage of the alpha-1A receptors causes relaxation of smooth muscles in the bladder neck and prostate, thus decreasing urinary outflow resistance in men.~Tamsulosin will be administered twice a day for two (2) days as an oral tablet containing 0.4 mg of the drug. It is usually administered 30 minutes after a meal to minimize plasma level variations. The 0.4 mg dose of tamsulosin that will be used in this trial has shown adequate safety and tolerability in multiple previously published studies as well as efficacy in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms in men.~A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1.
Study: NCT06242522

Intervention type: OTHER
Group type: OTHER
Intervention: Telephone interview
Description: Collection of gynaecology-obstetrics data on patients treated with AVELUMAB
Study: NCT06544577

Intervention type: DRUG
Intervention: ELacestrant
Description: 345 mg/day once daily oral dosing
Study: NCT06110884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy, speech therapy
Description: receive group music therapy in addition to traditional language therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: speech therapy
Description: receive only traditional language therapy
Study: NCT05925322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage & Connect Psychotherapy
Description: 9-weeks of weekly psychotherapy sessions focused on social reward exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Review and Psychoeducation (SRP)
Description: 9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
Study: NCT06516237

Intervention type: PROCEDURE
Group type: OTHER
Intervention: to determine molecular and epigenetic biomarkers
Description: In addition, up to 8 biopsies will be performed, at clinical judgment, in distal colon to determine molecular and epigenetic biomarkers.
Study: NCT05202197

Intervention type: OTHER
Intervention: Smart cupboard
Description: Development of a memory task with the help of a smart cupboard
Study: NCT06088680

Intervention type: DEVICE
Intervention: Glycar Pericardial Patch
Description: Glycar Bovine pericardial patch with AldeCaptm Technology (aka SJM with EnCaptm technology)
Study: NCT05053087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Continuous Infusion
Description: 0.2% continuous infusion 6mL/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Intermittent Bolus
Description: 0.2% intermittent bolus infusion 8mL every 2 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline filled catheter
Study: NCT05834608

Intervention type: BEHAVIORAL
Intervention: Mechanical ventilator-assisted ventilation
Description: After the intravenous anesthesia induction, mechanical ventilator-assisted ventilation with AutoFlow mode of the anesthesia machine (Draeger-Perseus) will be applied before intubation.
Study: NCT05480527

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous pulsed radiofrequency current
Description: Active treating group: 80 volts, 2Hz, 20 ms pulsed radiofrequency current will be applied to the tibial nerve trace in the ankle with electrodes. Sham group: Elelctrodes will be attached but radiofrequency current will not be applied.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous pulsed radiofrequency current
Description: Active treating group: 80 volts, 2Hz, 20 ms pulsed radiofrequency current will be applied to the tibial nerve trace in the ankle with electrodes. Sham group: Elelctrodes will be attached but radiofrequency current will not be applied.